Skip to Content


Phenylpropanolamine; Withdrawal of Approval of 13 New Drug Applications and 7 Abbreviated New Drug Applications

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 9744


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA) is withdrawing approval of 13 new drug applications (NDAs) and 7 abbreviated new drug applications (ANDAs) for products containing phenylpropanolamine. The basis for the withdrawals is that the products are no longer considered safe due to the association of phenylpropanolamine use with increased risk of hemorrhagic stroke. The holders of these NDAs and ANDAs have waived their opportunity for a hearing.


Effective February 20, 2014.

Start Further Info


Emily Helms Williams, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6280, Silver Spring, MD 20993-0002, 301-796-3381.

End Further Info End Preamble Start Supplemental Information


On November 3, 2000, the Director of FDA's Center for Drug Evaluation and Research (the Director) sent a letter to holders of NDAs and ANDAs for drug products containing phenylpropanolamine requesting that they voluntarily discontinue marketing any such products due to developments indicating an association between phenylpropanolamine use and increased risk of hemorrhagic stroke. Subsequently, in a notice published in the Federal Register on August 14, 2001 (66 FR 42665), the Director offered an opportunity for a hearing on a proposal to issue an order, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(e)) and 21 CFR 314.150(a)(2), withdrawing approval of 13 NDAs and 8 ANDAs for products containing phenylpropanolamine. (Although the August 14, 2001, notice stated that FDA proposed to withdraw approval of 16 NDAs and 8 ANDAs, the notice listed only 13 NDAs and 8 ANDAs.) The following products, all of which have been discontinued, were listed in the notice:

Table 1—NDAs and ANDAs for Which FDA Has Proposed To Withdraw Approval of the Applications

Application No.DrugApplicant
NDA 11-694Dimetane-DC SyrupA.H. Robins Co., P.O. Box 8299, Philadelphia, PA 19101.
NDA 12-152Ornade Extended-Release TabletSmithKline-Beecham, 1250 South Collegeville Rd., P.O. Box 5089, Collegeville, PA 19426.
NDA 12-436Dimetapp Extended-Release TabletWhitehall-Robins, 5 Giralda Farms, Madison, NJ 07940.
NDA 13-087Dimetapp ElixirDo.
NDA 18-050Corsym Extended-Release SuspensionMedeva Americas, Inc., 755 Jefferson Rd., P.O. Box 1710, Rochester, NY 14603.
NDA 18-099Contac Extended-Release CapsuleSmithKline Beecham Consumer Health, L.P., 1500 Littleton Rd., Parsippany, NJ 07054.
NDA 18-298Tavist-D Extended-Release TabletNovartis Consumer Health, Inc., 560 Morris Ave., Summit, NJ 07901.
NDA 18-556Demazin Extended-Release TabletSchering-Plough HealthCare Products, Three Oak Way, P.O. Box 603, Berkeley Heights, NJ 07922.
NDA 18-809Phenylpropanolamine Hydrochloride (HCl) Chlorpheniramine Maleate Extended-Release CapsuleSchwarz Pharma, 6140 West Executive Dr., Mequon, WI 53092.
NDA 19-410Hycomine SyrupEndo Pharmaceuticals, Inc., 500 Endo Blvd., Garden City, NY 11530.
NDA 19-411Hycomine Pediatric SyrupDo.
NDA 19-613Contac Extended-Release TabletNovartis Consumer Health, Inc.
NDA 20-640Tavist-D Extended-Release TabletDo.
ANDA 71-099Bromatapp Extended-Release TabletTeva Pharmaceuticals, USA, 1090 Horsham Rd., P.O. Box 1090, North Wales, PA 19454.
ANDA 88-359Drize Extended-Release CapsuleB. F. Ascher & Co., Inc., 15501 West 109th St., Lenexa, KS 66219.
ANDA 88-681Chlorpheniramine Maleate and Phenylpropanolamine HCl Extended-Release CapsuleChelsea Laboratories, 896 Orlando Ave., West Hempstead, NY 11552.
ANDA 88-687Biphetap ElixirMorton Grove Pharmaceuticals, Inc., 6451 Main St., Morton Grove, IL 60053.
ANDA 88-688Bromanate ElixirAlpharma, U.S. Pharmaceuticals Division, 333 Cassell Dr., suite 3500, Baltimore, MD 21224.
ANDA 88-723Bromanate DC SyrupDo.
ANDA 88-904Myphetane DC SyrupMorton Grove Pharmaceuticals, Inc.
ANDA 88-940Chlorpheniramine Maleate and Phenylpropanolamine HCl Extended-Release CapsuleGeneva Pharmaceuticals, Inc., 2555 West Midway Blvd., P.O. Box 446, Broomfield, CO 80038.

FDA issued the notice after an epidemiologic case-control study conducted by investigators at Yale University School of Medicine (Yale Hemorrhagic Stroke Project) demonstrated an association between phenylpropanolamine (an ingredient used in prescription and over-the-counter (OTC) drug products as a nasal decongestant to relieve stuffy nose or nasal congestion and in OTC weight control drug products to control appetite) and increased risk of hemorrhagic stroke. The notice included FDA's belief that the data from the Yale Hemorrhagic Stroke Project, taken together with spontaneous reports of hemorrhagic stroke and reports in the published medical literature, provided evidence that nasal decongestant and weight control drug products containing phenylpropanolamine are no longer safe. The Director proposed to withdraw approval of the NDA and ANDA products containing phenylpropanolamine based on her conclusion that they were no longer Start Printed Page 9745shown to be safe for use under the conditions that formed the basis upon which the applications were approved.

In the August 14, 2001, notice, FDA provided the NDA and ANDA holders an opportunity to request a hearing to show why approval of the NDAs or ANDAs should not be withdrawn. One company, KV Pharmaceutical, requested a hearing by letter dated September 13, 2001, but that request was subsequently withdrawn by letter dated October 15, 2001. No other party requested a hearing on this matter following publication of the notice in the Federal Register. As stated above, all products listed in the notice were subsequently discontinued.

Subsequent to the August 14, 2001, notice, one of the ANDAs listed in that notice was withdrawn. In a notice published in the Federal Register of February 20, 2002 (67 FR 7702), FDA withdrew approval of ANDA 71-099 for BROMATAPP Extended-Release Tablets after the application holder informed FDA that the product was no longer being marketed and requested withdrawal.

In a letter to FDA dated February 25, 2013, Pfizer requested on behalf of its subsidiaries, Wyeth Pharmaceuticals, Inc. and A.H. Robins, that FDA withdraw approval of NDA 11-694 for DIMETANE-DC under § 314.150(d), noting that the product has been discontinued and is no longer marketed. In that letter, Pfizer and its named subsidiaries waived any opportunity for a hearing provided under the August 14, 2001, notice. In a response letter of March 28, 2013, the Agency acknowledged A.H. Robins' agreement to permit FDA to withdraw approval of DIMETANE-DC under § 314.150(d) and to waive its opportunity for a hearing.

For the reasons discussed in the August 14, 2001 notice, the Director, under section 505(e)(2) of the FD&C Act and under authority delegated to her by the Commissioner, finds that new evidence of clinical experience, not contained in the applications listed in table 1 and not available at the time the applications were approved, shows that phenylpropanolamine is not shown to be safe for use under the conditions of use that formed the basis upon which the applications were approved (21 U.S.C. 355(e)(2)). Therefore, approval of the NDAs listed in table 1 is hereby withdrawn. Furthermore, the Director finds that the ANDAs listed in table 1 refer to the drugs that are the subject of the NDAs listed above. Therefore, as required under section 505(j)(6) of the FD&C Act, approval of the ANDAs listed in table 1 is also withdrawn.

Under 21 CFR 314.161 and 314.162(a)(1), FDA will remove the products containing phenylpropanolamine named in table 1 from the list of drug products with effective approvals published in FDA's “Approved Drug Products With Therapeutic Equivalence Evaluations.” FDA will not approve or accept ANDAs that refer to these drug products.

Start Signature

Dated: February 14, 2014.

Leslie Kux,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2014-03596 Filed 2-19-14; 8:45 am]